Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Parkinson DiseaseDyskinesia, Drug-InducedLevodopa
Interventions
DRUG

AFQ056

Trial Locations (22)

3050

Novartis Investigative Site, Parkville

3081

Novartis Investigative Site, Heidelberg

3181

Novartis Investigative Site, Prahran

33604

Novartis Investigative Site, Pessac

34128

Novartis Investigative Site, Kassel

35039

Novartis Investigative Site, Marburg

44791

Novartis Investigative Site, Bochum

46202

Novartis Investigative Site, Indianapolis

55041

Novartis Investigative Site, Lido di Camaiore

59037

Novartis Investigative Site, Lille

63003

Novartis Investigative Site, Clermont-Ferrand

72076

Novartis Investigative Site, Tübingen

80113

Novartis Investigative Site, Englewood

80131

Novartis Investigative Site, Napoli

80804

Novartis Investigative Site, München

94089

Novartis Investigative Site, Sunnyvale

K1G 4G3

Novartis Investigative Site, Ottawa

J9J 0A5

Novartis Investigative Site, Gatineau

J4V 2J2

Novartis Investigative Site, Greenfield Park

01307

Novartis Investigative Site, Dresden

07646

Novartis Investigative Site, Stadtroda

00163

Novartis Investigative Site, Roma

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY